Title:
USE OF MESENCHYMAL STEM CELLS IN TREATING IMMUNE-RELATED DISEASES
Document Type and Number:
WIPO Patent Application WO/2020/232940
Kind Code:
A1
Abstract:
Disclosed herein is a method of identifying a plurality of mesenchymal stem cells (MSCs) that are therapeutic to a subject having an immune-related disease, for example, arthritis. According to embodiments of the present disclosure, the MSCs exhibiting to the immune-related disease are characterized in having an immunosuppressive protein binding value (IPBv) greater than 170 toward indoleamine 2, 3-dioxygenase (IDO) after being exposed to 50-800 U/ml of IFN-γ. Also disclosed herein are uses of the identified MSCs for the manufacture of a medicament, and methods of treating an immune-related disease by use of the identified MSCs or medicament.
More Like This:
Inventors:
LEE SHING-MOU (CN)
CHEN HUNG-HSUAN (CN)
LAI WAN-LING (CN)
YU SAN-NI (CN)
CHEN HUNG-HSUAN (CN)
LAI WAN-LING (CN)
YU SAN-NI (CN)
Application Number:
PCT/CN2019/107750
Publication Date:
November 26, 2020
Filing Date:
September 25, 2019
Export Citation:
Assignee:
EMO BIOMEDICINE CORP (CN)
International Classes:
A61K35/28; A61P37/00; A61P37/06; C12N5/0775; G01N33/564
Domestic Patent References:
| WO2009114860A2 | 2009-09-17 | |||
| WO2019075090A1 | 2019-04-18 |
Foreign References:
| GB2550139A | 2017-11-15 | |||
| CN106148276A | 2016-11-23 |
Other References:
GUAN，Q.D. ET AL.: "Inducible indoleamine 2，3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells", CYTOTHERAPY, vol. 20, 31 December 2018 (2018-12-31), pages 639 - 648, XP055755756
LEE，S.ET AL.: "Developing a flow cytometry-based quantitative IDO assay to measure immune potency of mesenchymal stromal cells product for phaseⅠclinical trial", CYTOTHERAPY, vol. 21, no. 5, 31 May 2019 (2019-05-31), pages S37, XP055755763
PURCELL，J.W. ET AL.: "LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates", CANCER RESEARCH, vol. 78, no. 14, 15 July 2018 (2018-07-15), pages 4059 - 4072, XP055745280, DOI: 20191230142145A
LEE，S.ET AL.: "Developing a flow cytometry-based quantitative IDO assay to measure immune potency of mesenchymal stromal cells product for phaseⅠclinical trial", CYTOTHERAPY, vol. 21, no. 5, 31 May 2019 (2019-05-31), pages S37, XP055755763
PURCELL，J.W. ET AL.: "LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates", CANCER RESEARCH, vol. 78, no. 14, 15 July 2018 (2018-07-15), pages 4059 - 4072, XP055745280, DOI: 20191230142145A
Attorney, Agent or Firm:
CHINA ZHENGHE INTELLECTUAL PROPERTY AGENCY (CN)
Download PDF: